Angelini Ventures在Nuevocor生物技术公司投资45M美元,用于心脏病基因治疗。 Angelini Ventures leads $45M investment in biotech firm Nuevocor for heart disease gene therapies.

Angelini Ventures公司共同领导了对Nuevocor的4 500万美元投资,Nuevocor是一家生物技术公司,从事基因心脏病症治疗工作。 Angelini Ventures has co-led a $45 million investment in Nuevocor, a biotech firm working on therapies for genetic heart conditions. 这标志着Angelini首次进入亚洲 和基因治疗。 This marks Angelini's first foray into Asia and gene therapy. 这笔资金将支持Nuevocor的主要候选者NVC-001临床试验,该试验针对的是LMNA基因突变造成的罕见心脏病。 The funding will support clinical trials for Nuevocor’s lead candidate, NVC-001, which targets a rare heart condition caused by LMNA gene mutations. Kurma Partners和高亮资本等现有投资者也加入了这一回合,目的是推进该公司的创新心脏病治疗。 Existing investors like Kurma Partners and Highlight Capital also joined the round, aimed at advancing the company’s innovative heart disease treatments.